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Abstract
We have recently identified RFamide-related peptide (RFRP) gene that would encode three peptides (i.e., RFRP-1, -2, and
-3) in human and bovine, and demonstrated that synthetic RFRP-1 and -3 act as specific agonists for a G protein-coupled
receptor OT7T022. However, molecular characteristics and tissue distribution of endogenous RFRPs have not been
determined yet. In this study, we prepared a monoclonal antibody for the C-terminal portion of rat RFRP-1. As this
antibody could recognize a consensus sequence among the C-terminal portions of rat, human, and bovine RFRP-1, we
purified endogenous RFRP-1 from bovine hypothalamus on the basis of immunoreactivity to the antibody. The purified
bovine endogenous RFRP-1 was found to have 35-amino-acid length that corresponds to 37-amino-acid length in human
and rat. We subsequently constructed a sandwich enzyme immunoassay using the monoclonal antibody and a polyclonal
antibody for the N-terminal portion of rat RFRP-1, and analyzed the tissue distribution of endogenous RFRP-1 in rats.
Significant levels of RFRP-1 were detected only in the central nervous system, and the highest concentration of RFRP-1 was
detected in the hypothalamus. RFRP-1-positive nerve cells were detected in the rat hypothalamus by immunohistochemical
analyses using the monoclonal antibody. In culture, RFRP-1 lowered cAMP production in Chinese hamster ovary cells
expressing OT7T022 and it was abolished by pre-treatment with pertussis toxin, suggesting that OT7T022 couples Gi/Go in
the signal transduction pathway. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
A number of bioactive peptides with RFamide
structure at their C-termini (e.g., FMRFamide iso-
lated from the bivalve mollusc Macrocallista nimbosa
[1]) have been found particularly in invertebrates,
and they are referred to as RFamide peptides [2].
However, in vertebrates, only a few RFamide pep-
tides have been thus far reported. LPLRFamide and
gonadotropin-inhibitory hormone (GnIH), have been
puri¢ed from chicken and quail brain extracts respec-
tively [3,4], but their genes are not identi¢ed yet.
Three RFamide peptide genes have been identi¢ed
in mammals. One of these codes for two peptides,
neuropeptide FF (NPFF) and neuropeptide AF
(NPAF), which have been initially characterized to
modulate the action of morphine [5,6]. Another co-
des for prolactin-releasing peptide (PrRP) which we
have identi¢ed as the endogenous ligand of the
G protein-coupled receptor (GPCR) hGR3 [7].
Although PrRP was initially demonstrated to have
a speci¢c stimulatory activity on the secretion of pro-
lactin (PRL) [8,9] from rat anterior pituitary cells in
vitro and in vivo [7,10], to date it has been proven to
have a variety of functions [11^14]. We have recently
succeeded in the identi¢cation of the other novel
mammalian RFamide peptide gene through analyz-
ing human genome and cDNA sequences in the data-
base, and named it RFamide-related peptide (RFRP)
gene [15]. By isolating human, bovine, rat, and
mouse RFRP cDNAs, we have found that human
and bovine RFRP preproproteins encoded by the
cDNAs might generate three kinds of mature pep-
tides (i.e., RFRP-1, -2, and -3), whereas those of
rodents would generate RFRP-1 and RFRP-3 with-
out RFRP-2. We have subsequently demonstrated
that synthetic RFRP-1 and RFRP-3 speci¢cally
bind to a novel GPCR, OT7T022, by applying the
strategy that we have previously established to iden-
tify ligands for orphan GPCRs [16]. The expression
of RFRP mRNA has been detected mainly in the eye
and hypothalamus, while the highest expression of
OT7T022 mRNA has been detected in the hypothal-
amus in rats. Intracerebroventricular administration
of RFRP-1 caused the elevation of plasma PRL lev-
els in rats, suggesting that RFRPs have regulatory
functions in PRL secretion.
Although we have demonstrated that RFRPs
could speci¢cally interact with OT7T022 in vitro
and function even in vivo in rats by utilizing syn-
thetic RFRPs deduced on the basis of the amino
acid sequence from the cDNA, there has been no
information on the molecular characteristics of en-
dogenous RFRPs. In this study, we prepared anti-
bodies for rat RFRP-1. In our preliminary studies,
the contents of immunoreactive RFRP-1 (ir-RFRP-
1) in rat brains appeared to be too low level to pu-
rify. We hence switched to purify endogenous
RFRP-1 from bovine hypothalamic tissue extracts
through detecting immunoreactivity with the anti-
body, and then analyzed the molecular structure of
the puri¢ed bovine endogenous RFRP-1. We subse-
quently analyzed the distribution of ir-RFRP-1 in rat
tissues by a sandwich enzyme immunoassay (EIA)
and immunostaining. In addition, we con¢rmed the
interaction of the endogenous RFRP-1 with
OT7T022, and analyzed the intracellular signal trans-
duction mechanism via OT7T022. We believe this is
the ¢rst report on analyses for the molecular charac-
teristics and tissue distribution of endogenous
RFRP-1.
2. Materials and methods
2.1. Preparation of synthetic peptides
RFRPs and PrRP were synthesized using auto-
matic peptide synthesizer (Model 430, PE Biosys-
tems) as described previously [7,15]. Human RFRP-
1 with 37-amino-acid length (human RFRP-1-37)
was also produced by the application of a recombi-
nant DNA technology and Cys-speci¢c cyanylation
reaction as described previously [17]. Other peptides
were purchased from commercial suppliers (Peptide
Institute or Bachem).
2.2. Immunological procedures
A monoclonal antibody for the C-terminal portion
of rat RFRP-1 was prepared as follows. A synthetic
peptide with Cys at the N-terminus (CVPHSAA-
NLPLRF-NH2 : rat RFRP-1C) was conjugated
with bovine serum albumin (BSA; Pierce) using
BBAMCR 14788 21-9-01
S. Fukusumi et al. / Biochimica et Biophysica Acta 1540 (2001) 221^232222
N-(Q-maleimidobutyryloxy)succinimide (GMBS; Do-
jindo). The resultant conjugate at 100 Wg admixed
with TiterMax Gold (CytRx corporation) was sub-
cutaneously injected into BALB/c mice (female,
8 weeks old) twice at 2-week intervals. One week
after the last subcutaneous injection, 50 Wg of the
conjugate was intravenously injected into each
mouse. Four days after the intravenous injection,
spleen cells obtained from each immunized mouse
were fused with mouse myeloma cells (P3-X63Ag8-
U1) by using polyethylene glycol 1500 (Boehringer)
according to the manufacturer’s instruction. A hy-
bridoma clone, 1F3, that produced an antibody for
rat RFRP-1C was isolated, and then cultured in an
INTEGRA CL-1000 system (Integra Biosciences).
The monoclonal antibody produced from 1F3 was
puri¢ed from the culture supernatant with a HiTrap
rProtein A column (Amersham Pharmacia Biotech).
The isotype of the puri¢ed antibody was determined
with a Mouse mAb isotyping kit (Amersham Phar-
macia Biotech).
Rat RFRP-1C was conjugated with horseradish
peroxidase (HRP; Boehringer) using GMBS. After
puri¢cation, the HRP-conjugated rat RFRP-1C was
puri¢ed, and used as a tracer. For competitive EIA,
the puri¢ed 1F3 monoclonal antibody (50 Wl) appro-
priately diluted with Bu¡er A phosphate-bu¡ered sa-
line (PBS) containing 2 mM EDTA, 0.4% BSA, 0.1
M NaCl, and 0.1% micro-O-protect (Boehringer) was
added to each well of goat anti-mouse IgGAM-
coated microplates, and then each sample dissolved
in Bu¡er A (50 Wl) was added to the well. After
incubation at 4‡C for 16 h, HRP-conjugated rat
RFRP-1C was added to the well, and then the micro-
plates were incubated at room temperature for 2 h.
The microplates were washed with PBS containing
0.1% Tween 20 (Sigma) (PBS-T), and then the
HRP activity retained in each well was measured
with a TMB microwell peroxidase system (Kirke-
gaard and Perry Labs). As a reference to quantify
RFRP-1, we used human RFRP-1 with 12-amino-
acid length (i.e., MPHSFANLPLRF-NH2) because
both human RFRP-1 and rat RFRP-1C were equally
detected by this EIA.
A polyclonal antibody for N-terminal portion of
rat RFRP-1 was prepared as follows. A synthetic
peptide with Cys at the C terminus (SVTFQELK-
DWC: rat RFRP-1N) was conjugated with BSA by
the same method as described above. After the re-
sultant conjugate at 300 Wg was admixed with Titer-
Max Gold, it was subcutaneously injected into rab-
bits four times at 2-week intervals. Antisera were
obtained after the last injection. The IgG fraction
of the anti-rat RFRP-1N antibody was then puri¢ed
from a proper antiserum through an a⁄nity column
conjugated with rat RFRP-1N using a SulfLink kit
(Pierce).
Rat endogenous RFRP-1 was quanti¢ed with a
sandwich EIA using anti-rat RFRP-1N and anti-rat
RFRP-C antibodies. The anti-rat RFRP-1N poly-
clonal antibody was labeled with HRP as described
elsewhere [18]. For sandwich EIA, the 1F3 monoclo-
nal antibody was coated to 96-well microplates at 10
Wg/ml in 0.1 M carbonate bu¡er (100 Wl) at pH 9.5.
These plates were washed with PBS-T, and each sam-
ple dissolved in Bu¡er A (100 Wl) was added to the
well. After incubation at 4‡C for 24 h, the micro-
plates were washed with PBS-T, and HRP-conju-
gated anti-rat RFRP-1N Fab was added to each
well. After incubation at 4‡C for 16 h, the micro-
plates were washed with PBS-T, and then the HRP
activity retained in each well was measured with a
TMB microwell peroxidase system. As a reference to
quantify rat endogenous RFRP-1, we used synthetic
rat RFRP-1-37.
Histological procedure is as follows. Under pento-
barbital anesthesia, adult male Sprague^Dawley rats
injected with 90 Wg colhicine (Nacalai Tesque) into
the lateral ventricle 2 days before sacri¢ce were per-
fused via the left cardiac ventricle with 5% acrolein
(Aldrich) in 0.1 M phosphate bu¡er. Serial frozen
frontal sections (25 Wm thick) were cut from the
brain. The sections were washed with PBS treated
with 0.5% sodium pyrosulfate for 10 min, and 1.0%
sodium borohydride for 10 min. They were then pro-
cessed by the avidin^biotin complex immunocyto-
chemical method using the monoclonal antibody
1F3 (20 Wg/ml). Preincubation of the antibody with
human RFRP-1-12 diminished the immunoreactivity
on the sections.
2.3. Extraction of tissues
Frozen bovine hypothalamic tissues (2 kg) were
boiled, homogenized in 1 M acetic acid, and ex-
tracted overnight. The resultant supernatant was col-
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lected by centrifugation, and then subjected to vari-
ous chromatography. Rat tissues were obtained from
male or female Wistar rats (8 weeks old) immediately
after decapitation, and then frozen at 380‡C until
used. Plasma was obtained as described elsewhere
[19]. Each tissue (0.2^2 g) or plasma was boiled,
and then homogenized in 1 M acetic acid. After
the centrifugation, the resultant supernatant was de-
salted with a Sep-Pak Vac C18 column, and then
used as a sample for the sandwich EIA.
2.4. Chromatography
The bovine hypothalamic extract added with
0.05% tri£uoroacetic acid (TFA) was applied to a
Preparative C18 column (Waters), and the elution
was performed with step-wise increments of 10%,
30%, and 50% CH3CN with 0.1% TFA. The contents
of ir-RFRP-1 were determined with the competitive
EIA using the monoclonal antibody 1F3. Ir-RFRP-
1-positive fraction was eluted in 30% CH3CN. It was
further fractionated by a HiPrep CM-Sepharose FF
(Amersham Pharmacia Biotech) column with step-
wise increments of 0.1, 0.2, 0.5, and 1.0 M NaCl in
20 mM CH3COONH4 (pH 4.7) containing 10%
CH3CN. After precipitation with acetone, the 0.2
M CH3COONH4 fraction was serially fractionated
on a Resource RPC column (Amersham Pharmacia
Biotech) with a linear gradient from 10% to 30%
CH3CN with 0.1% TFA, and a TSK-gel CM-2SW
column (Toso) with a linear gradient from 0.2 to 0.6
M NaCl in 20 mM CH3COONH4 at pH 4.7. The
fractions containing ir-RFRP-1 were subsequently
fractionated on a Vydac diphenyl 219TP52 column
(Separation Corp.). Ir-RFRP-1 was eluted in frac-
tions at 23% in a linear gradient from 21% to 25%
CH3CN with 0.1% TFA. The fractions containing ir-
RFRP-1 were ¢nally applied to a WRPC C2/C18 SC
2.1/10 column (Amersham Pharmacia Biotech) in
SMART system (Amersham Pharmacia Biotech).
Tissue samples for gel ¢ltration were collected as
follows. Acetic acid extracts obtained from ten rat
brains were applied to a Sep-Pak Vac C18 column,
and then eluted with step-wise increments of 10%,
30%, and 50% CH3CN containing 0.1% TFA. The
fraction eluted with 30% CH3CN was diluted with
twofold volume of 20 mM CH3COONH4 at pH 4.7,
and then applied to a HiTrap CM-Sepharose FF
5-ml column (Amersham Pharmacia Biotech). Elu-
tion from CM-Sepharose was performed with a lin-
ear gradient from 0 to 500 mM NaCl in 20 mM
CH3COONH4 at pH 4.7 containing 10% CH3CN.
Ir-RFRP-1-positive fractions were precipitated with
threefold volumes of acetone, and then applied on
gel ¢ltration chromatography using a Superdex Pep-
tide PC 3.2/30 column in SMART system (Amer-
sham Pharmacia Biotech) in 40% CH3CN containing
0.1% TFA at a £ow rate of 25 Wl/min.
2.5. Peptide sequencing and mass spectrometry
The N-terminal sequence of the puri¢ed peptide
was determined using a Model 491 cLC protein se-
quencer (PE Biosystems). Electrospray ionization
(ESI) mass spectrometry was performed on a LCQ
ion-trap mass spectrometer (ThermoQuest) equipped
with a nanoESI source (Protana). The puri¢ed pep-
tide was dissolved in 50% (v/v) CH3CN with 1%
HCOOH, and then loaded into a gold-coated capil-
lary (Protana). ESI conditions were as follows: capil-
lary temperature, 160‡C; ESI voltage, 1.5 kV; capil-
lary voltage, 46 V. The molecular mass of the peptide
was calculated using a Bioworks software (Thermo-
Quest).
2.6. cAMP production assay
We prepared Chinese hamster ovary (CHO) cells
transfected with human OT7T022 cDNA, and then
examined the inhibitory activities of samples on
cAMP production in these cells in the presence of
forskolin according to the method as described pre-
viously [15,20]. For the treatment of pertussis toxin
(PTX), these cells were incubated with 100 ng/ml of
PTX (P-9480, Sigma Chemical Co.) overnight before
the cAMP production assays.
3. Results
3.1. Construction of competitive EIA using anti-rat
RFRP-1C antibody
To detect endogenous bovine RFRP-1, we pre-
pared a mouse monoclonal antibody (1F3 with
IgG1 heavy and U light chains) that was capable of
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recognizing C-terminal portion of rat RFRP-1, and
then constructed a competitive EIA using this anti-
body and HRP-conjugated rat RFRP-1 C-terminal
fragment as a tracer. As shown in Fig. 1, this EIA
could e⁄ciently detect both human RFRP-1-12 and
LPLRFamide. It could also detect the non-amidated
form of LPLRF and Met-Enkephalin-RFamide (i.e.,
YGGFMRF-NH2), though the e⁄cacy of the detec-
tion evidently decreased. However, it did not detect
other peptides with C-terminal RFamide, that is, bo-
vine NPFF (i.e., FLFQPQRF-NH2) and NPAF
(i.e., AGEGLSSPFWSLAAPQRF-NH2) or human
RFRP-3 with 8-amino-acid length (i.e., VPNLPQ-
RF-NH2 : RFRP-3-8). These results indicate that
this EIA principally detects the C-terminal portion
of rat RFRP-1, probably the epitope of LPLRF-
NH2, which is a consensus sequence among bovine,
rat and human (Fig. 2). We thus decided to employ
this EIA to detect endogenous RFRP-1 in the
process of the puri¢cation from bovine hypothal-
ami.
3.2. Puri¢cation of endogenous bovine RFRP-1
RFRP mRNA has been demonstrated to be
mainly expressed in the hypothalamus in rats [15].
However, it was di⁄cult to collect rat hypothalamus
in a large quantify su⁄cient to purify endogenous
RFRP-1. We thus employed bovine hypothalamic
tissues as a starting material to purify endogenous
RFRP-1. Puri¢cation was performed with a combi-
nation of various chromatography through monitor-
ing ir-RFRP-1 with the competitive EIA. Fig. 3
shows the pro¢le of the last chromatography with
a reverse-phase HPLC using a WRPC C2/C18 SC
2.1/10 column. Ir-RFRP-1 was eluted as a single
peak in a gentle linear gradient from 22% to 23%
CH3CN with 0.1% TFA, and this peak coincided
with that of absorbance at 215 nm. We eventually
obtained 58 pmol of the puri¢ed RFRP-1. The frac-
tion containing puri¢ed RFRP-1 was subjected to
microsequencing and mass spectrometry. The micro-
sequencing revealed the following N-terminal se-
quence: SLTFEEVKDXAPKIKMNKPV (X was
ambiguous due to low yield of the PTH-amino
acid) (Fig. 4A), corresponding to the sequence from
Ser58 to Val77 in the bovine RFRP preproprotein
(Fig. 2). The molecular mass of the puri¢ed RFRP-1
was determined to be 3996.8 þ 0.6 with mass spec-
trometry (Fig. 4B). This value agreed with the calcu-
lated molecular mass of 3996.8 in the amidated form
of RFRP-1 with 35-amino-acid length that would
generate from Ser58 to Phe92 from the bovine
RFRP preproprotein (Fig. 2). These results indicate
that the puri¢ed bovine RFRP-1 consists of the fol-
lowing amino acid residues: SLTFEEVKDWAPKI-
KMNKPVVNKMPPSAANLPLRF-NH2.
3.3. Construction of sandwich EIA to quantify rat
endogenous RFRP-1
To quantify precisely endogenous rat RFRP-1, we
prepared a rabbit polyclonal antibody for the N-ter-
minal sequence (i.e., SVTFQELKDW) of rat RFRP-
1-37. This antibody could recognize rat RFRP-1-37,
but not other RFamide peptides including human
RFRP-1-37, NPFF, and NPAF (data not shown).
Fig. 1. Detection of RFRP-1 with competitive EIA. The mono-
clonal antibody (1F3) which could detect the C-terminal por-
tion of RFRP-1 was added to each well of the anti-mouse
IgGAM-coated microplates, and then samples, that is, human
RFRP-1-12 (b), LPLRFamide (R), human RFRP-3-8 (F),
PQRFamide (8), Met-Enkephalin-RFamide (O), Met-Enke-
phalin-RF (a), LPLRF (E), and PQRF (7), were added to the
well, respectively. After incubation for 16 h, HRP-conjugated
rat RFRP-1C was added to the well, and then the plates were
incubated for 2 h. After the plates were washed, the HRP activ-
ity retained in each well was measured. Data are expressed as
means in duplicate assays. B, absorbance in the presence of
samples; B0, that in the absence of samples.
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By utilizing this polyclonal antibody labeled with
HRP and the monoclonal antibody for the C-termi-
nal portion of rat RFRP-1, we constructed a sand-
wich EIA to quantify rat endogenous RFRP-1. This
sandwich EIA could detect at least 0.4 fmol/well of
rat RFRP-1-37. However, it did not detect other
peptides with the RFamide structure, including hu-
man RFRP-1-37, human RFRP-1-12, LPLRFamide,
Met-Enkephalin-RFamide, NPFF, and NPAF (data
not shown). These results indicate that this EIA can
detect speci¢cally rat RFRP-1-37.
3.4. Analysis for distribution of RFRP-1 in rat tissues
We measured the contents of endogenous RFRP-1
in rat tissues with the sandwich EIA. As shown in
Fig. 5, signi¢cant levels of ir-RFRP-1 were detected
principally in the central nervous system, and the
highest concentration was detected in the hypothal-
amus (2800 fmol/g wet tissue). High concentrations
of ir-RFRP-1 were detected in the thalamus (1000
fmol), midbrain (880 fmol), and optic nerve (440
fmol). Moderate levels of ir-RFRP-1 were detected
in the cerebral cortex (140 fmol), striatum (210 fmol),
and medulla oblongata (250 fmol), and low levels in
the hippocampus (29 fmol) and cerebellum (33 fmol).
Fig. 3. Pro¢le of WRPC C2/C18 SC 2.1/10-column chromatogra-
phy in puri¢cation of endogenous RFRP-1. Ir-RFRP-1 in each
fraction detected with the competitive EIA is shown as a closed
column. The dotted lines and jagged lines indicate the percent-
age of CH3CN and absorbance, respectively.
Fig. 2. Amino acid sequences of bovine, rat, and human RFRP preproprotein. The highlighted residues indicate the endogenous bo-
vine RFRP-1 sequence. The arrowhead indicates the expected cleavage site of a secretary signal peptide. The motif that generates the
C-terminal RFamide structure is boxed with a solid line. The motif that may generate the C-terminal RFamide-like structure is boxed
with a dotted line.
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However, it was undetectable (6 2.1 fmol) in the
peripheral tissues including plasma.
To analyze more detailed distribution of RFRP-1
in the hypothalamus, we conducted immunohisto-
chemical analyses using the monoclonal anti-
body 1F3. We used the acrolein ¢xation method be-
cause we obtained better speci¢c signals by acrolein
than by paraformaldehyde. As shown in Fig. 6,
ir-RFRP-1 was detected in neurons and ¢bers within
the caudal portion of the hypothalamus; the periven-
tricular nucleus (PerVN) and the portion around or
above the ventromedial nucleus (VMN) of the hypo-
thalamus. More precise location of neurons with
ir-RFRP1 was between VMN and dorsomedial nu-
cleus DMN and extended to the lateral hypothalamic
area.
3.5. Analysis for molecular characteristics of
endogenous rat RFRP-1
We analyzed the molecular size of endogenous
RFRP-1 in the rat brain by gel ¢ltration in combi-
nation with the competitive EIA. Acetic acid extracts
from the rat brain were partially puri¢ed, and then
subjected to the EIA. In a HiTrap CM-Sepharose FF
column chromatography, the immunoreactivities
were detected separately in a minor peak of P1 and
a major peak of P2 (data not shown). After fractions
containing P1 and P2 were treated with acetone, the
resultant supernatants were respectively applied to a
Superdex peptide PC 3.2/30-column chromatogra-
phy. In P1 ir-RFRP-1 was eluted at the position
corresponding to human RFRP-1-12 (Fig. 7A),
whereas in P2 it was eluted at that corresponding
to rat RFRP-1-37 (Fig. 7B). By the sandwich EIA,
we could detect ir-RFRP-1 only in P2 but not in P1
(data not shown). Thus we could not rule out the
Fig. 5. Quanti¢cation of endogenous RFRP-1 in rat tissues by
EIA. The contents of ir-RFRP-1 were determined with the
sandwich EIA. A calibration curve to quantify the contents of
ir-RFRP-1 was obtained using synthetic rat RFRP-1-37. Data
are expressed as mean þ S.E.M. in multiple assays (n = 4 or 5),
except for the optic nerve, which was pooled from ¢ve rats.
Fig. 4. Structural analysis for puri¢ed endogenous bovine
RFRP-1. (A) Yield of phenylthiohydantoin (PTH)-amino acid
at each cycle in Edman degradation. X is an unidenti¢ed resi-
due. (B) NanoESI mass spectrum showing the multiply charged
ions. Puri¢ed bovine RFRP-1 (11 pmol) was dissolved in 3 Wl
of 50% CH3CN with 1% HCOOH, loaded into a gold-coated
capillary, and analyzed with a LCQ mass spectrometer. Based
on each m/z value of the multiply changed ion signals
([M+nH]n), the molecular mass of bovine RFRP-1 was calcu-
lated as 3996.8 þ 0.6 with Bioworks software.
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Fig. 8. Inhibition of cAMP production in CHO cells expressing
OT7T022 by endogenous rat and human RFRP-1. CHO cells
expressing human OT7T022 cultured in 24-well microplates
were treated with the indicated concentrations of human
RFRP-1-12 (a), human RFRP-1-37 (F), rat RFRP-1-37 (7),
human RFRP-2-12 (R), human RFRP-3-8 (E), PQRFamide
(8), LPLRFamide (b), and NPFF (O), in the presence of
1 WM forskolin. After 30 min incubation, the amount of intra-
cellular cAMP in each well was measured with EIA. Data are
expressed as mean þ S.E.M. of % in triplicate assays.
Fig. 7. Gel ¢ltration analysis for endogenous rat RFRP-1.
Fractions containing ir-RFRP-1 (P1 and P2) prepared from rat
brain extracts through a HiTrap CM-Sepharose FF column
chromatography were separately subjected onto a gel ¢ltration
chromatography. (A) Gel ¢ltration of P1. (B) Gel ¢ltration of
P2. Ir-RFRP-1 was detected with the competitive EIA using the
monoclonal antibody 1F3 that could detect the C-terminal por-
tion of RFRP-1. The arrows indicate the positions of synthetic
rat RFRP-1-37 (a) and human RFRP-1-12 (b) eluted in the
same chromatography.
Fig. 6. Immunohistochemical analysis for RFRP-1 in rat hypothalamus. Ir-RFRP-1 in the rat hypothalamus was detected by staining
with the monoclonal antibody 1F3. DMN, dorsomedial nucleus; VMN, ventromedial nucleus; 3V, third ventricle. The right picture
was a magni¢ed one from the area boxed in the left picture. Scale bars: 500 Wm on the left and 200 Wm on the right.
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possibility that P1 might contain substances unre-
lated to RFRP-1. These results indicate that the ma-
jor component of endogenous rat RFRP-1 is rat
RFRP-1-37.
3.6. Interaction of endogenous RFRP-1 with
OT7T022
We prepared CHO cells expressing human
OT7T022 and examined the interaction of endoge-
nous RFRP-1 with OT7T022. As shown in Fig. 8,
both synthetic rat RFRP-1-37 and human RFRF-1-
37 e⁄ciently inhibited cAMP production in these
cells stimulated with forskolin (i.e., e¡ective doses
of 50% (ED50) at 30 and 21 nM, respectively). Their
potency was comparable with LPLRFamide (ED50 at
36 nM) but less than human RFRP-1-12 (ED50 at 4.5
nM) or human RFRP-3-8 (ED50 at 9.9 nM) and
greater than NPFF (ED50 at 140 nM) and PQRFa-
mide (ED50 at s 1000 nM). They showed almost
comparable activity on CHO cells expressing rat
OT7T022 in this assay (data not shown). Synthetic
human RFRP-2 with 12-amino-acid length (RFRP-
2-12) did not show agonistic activity on OT7T022.
These results indicate that the endogenous type of
RFRP-1 certainly acts as a speci¢c agonist for
OT7T022.
To elucidate the mechanism for the inhibition of
cAMP production, we treated these cells with PTX.
As shown in Fig. 9, the inhibition of cAMP produc-
tion induced by human RFRP-1-12 was almost com-
pletely abrogated by the pre-treatment with PTX.
4. Discussion
In this study, we puri¢ed endogenous bovine
RFRP-1 and determined its structure. The puri¢ed
endogenous bovine RFRP-1 was found to consist of
35 amino acid residues. This result indicates that the
N-terminus of the mature bovine RFRP-1 is pro-
duced by cleavage between Arg56 and Ser57 in the
bovine RFRP preproprotein (Fig. 2). As basic amino
acid residues are generally considered to be potential
sites receiving cleavage by proteases, this cleavage
appears to be rational in this point. However, in
the sequence of the endogenous bovine RFRP-1,
there are other ¢ve basic amino acid residues, that
is, Lys64, 69, 71, 74, and 79 (Fig. 2). It was thus
unexpected that endogenous RFRP-1 had a long
N-terminal portion. In the puri¢cation process, we
could not detect shorter forms of endogenous bovine
RFRP-1 at least as major components. Although we
do not know the reason why the cleavage occurs
selectively between Arg56 and Ser57, a three-dimen-
sional conformation might in£uence the susceptibili-
ty of respective sites to proteases. To be interested,
the two amino acid residues (Arg and Ser) at the
cleavage site were completely conserved among
mammalian species [15]. These results suggest that
a similar processing to produce endogenous bovine
RFRP-1 occurs in other species, that is, RFRP-1
molecules with 37-amino-acid length generate from
the human, rat, and mouse preproproteins.
As we have reported previously [15] and showed in
this study, shorter C-terminal RFRP-1 peptides (i.e.,
human RFRP-1-12) had su⁄cient agonistic activities
on OT7T022. These results indicate that a core struc-
ture to interact with the receptor resides in the
C-terminal portion. We have recently reported that
a bioactive peptide, apelin, has 36-amino-acid length
as a main endogenous form and its core structure to
interact with the receptor (APJ) resides within the
C-terminal 13 residues [21]. We have demonstrated
that the long N-terminal portion of apelin functions
Fig. 9. E¡ect of PTX treatment on the inhibitory activity of
RFRP-1 in cAMP production. CHO cells expressing human
OT7T022 cultured in 24-well microplates were pre-incubated
overnight in the absence (PTX(3)) or in the presence (PTX(+))
of PTX at 100 ng/ml. Then the cells were incubated without
samples (closed columns), with 1 WM forskolin (open columns),
or with forskolin and 0.1 WM human RFRP-1-12 (dotted col-
umns) for 30 min. The amounts of intracellular cAMP were
measured with EIA. Data are expressed as mean þ S.E.M. in
triplicate assays.
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to modulate the interaction with the receptor [22].
Further studies will be necessary to reveal the func-
tion of the long N-terminal portion of RFRP-1. In
addition, we found that the RFRP-1-induced inhibi-
tion of cAMP production in CHO cells expressing
OT7T022 was abolished by the treatment with
PTX. These results suggest that OT7T022 couples
to Gi/Go.
By the sandwich EIA speci¢c for rat RFRP-1-37,
we revealed the tissue distribution of endogenous
RFRP-1 in rat tissues. Ir-RFRP-1 was detected
mainly in the central nervous system. The highest
concentration of ir-RFRP-1 was detected in the hy-
pothalamus, and high levels of ir-RFRP-1 in the
thalamus and midbrain. We con¢rmed the distribu-
tion of endogenous RFRP-1 in the hypothalamus by
immunostaining with the monoclonal antibody 1F3.
In this analysis, we found that ir-RFRP-1-positive
cell bodies were distributed in the PerVN and
VMN. These results agreed well with our previous
data that RFRP mRNA is highly expressed in the
PerVN and VMN in rats. In addition, we detected ir-
RFRP-1-positive nerve ¢bers in the hypothalamus,
suggesting that processes from neurons producing
RFRP-1 are distributed in various regions in the
brain. We are now under investigation in this point.
We have previously reported that a high level of
RFRP mRNA is detectable in the eye in addition
to the hypothalamus in rats [15], but we could not
detect a signi¢cant amount of ir-RFRP-1 in the eye
by the EIA in this study. In addition, even in the
immunohistochemical analysis using the monoclonal
antibody 1F3, we could not detect evident ir-RFRP-
1 in the retina. The discrepancy in the distribution of
RFRP mRNA and ir-RFRP-1 in the eye still remains
to be resolved. On the other hand, OT7T022 mRNA
has been detected not only in the central nervous
system but also in the testis [15]. However, we de-
tected neither ir-RFRP-1 nor RFRP mRNA at sig-
ni¢cant levels in the testis. These results indicate that
RFRPs do not function in the testis, although we
cannot rule out the possibility that other RFamide
peptides act on OT7T022 in this tissue.
As we have previously pointed out, the sequences
of NPFF, NPAF, and RFRPs are closely related.
Several groups have very recently reported the iden-
ti¢cation of receptors for NPFF and NPAF. A
GPCR, HLWAR77, has been reported to act as a
speci¢c receptor for NPFF and NPAF [23].
HLWAR77 is nearly identical to NPGPR previously
reported by another group [24]. It has been also re-
ported that there are two receptors (i.e., NPFF1 and
NPFF2) for NPFF [25]. HLWAR77/NPGPR is iden-
tical to NPFF2, while OT7T022 is identical to
NPFF1. However, the binding a⁄nity of NPFF on
OT7T022/NPFF1 is reportedly less than that on
HLWAR77/NPGPR/NPFF2 [25]. As shown in this
study, the agonistic activity of NPFF on OT7T022
appeared to be less than RFRPs in the cAMP-pro-
duction-inhibitory assay using CHO cells, suggesting
that RFRPs principally work as ligands for
OT7TO22. Future studies to determine the cross re-
activity of RFRPs on HLWAR77/NPGPR/NPFF2
and OT7T022/NPFF1 will be necessary.
As we have previously reported [15], the sequence
of the chicken LPLRFamide [3] completely matches
with the C-terminal sequence of RFRP-1. In addi-
tion, an RFamide peptide, GnIH [4], which has been
recently isolated from the quail brain, has a very
similar sequence (i.e., SIKPSAYLPLRF-NH2) to
the C-terminal portion of RFRP-1. The amino acid
sequence similarity among LPLRFamide, GnIH, and
RFRP-1 strongly suggest that these peptide genes
have evolved and diversi¢ed from the same ancestor.
We have showed that the administration of human
RFRP-1-12 into the rat third ventricle induces the
elevation of plasma PRL levels [15]. NPFF, NPAF,
and PrRP reportedly have a variety of biological
activities [26,27,11^14]. Therefore, there is the possi-
bility that RFRPs also have various unknown func-
tions. LPLRFamide reportedly elevates arterial
blood pressure and induces excitation in neurons in
rats [3,28]. GnIH reportedly inhibits luteinizing hor-
mone secretion in primary-cultured quail pituitary
cells [4]. Future studies are required to determine
whether RFRPs have similar functions to LPLRFa-
mide or GnIH.
In this study, we demonstrated the existence of
endogenous RFRP-1 and clari¢ed its structure and
distribution. However, the molecular characteristics
of endogenous RFRP-2 and -3 remain to be eluci-
dated. Further studies on RFRP and its receptor will
give insight into the physiological signi¢cance of
RFamide peptides in mammals.
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